Analyzing DNA from Blood and Tissue of Lung Cancer Patients
Molecular and Genetic Analysis of Lung Cancer
This study is trying to see how DNA from blood and tissue samples can help us understand the genetic factors that affect lung cancer in patients.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 120 Years |
| Sex | All |
| Sponsor | Massachusetts General Hospital Academic / other |
| Locations | 2 sites (Boston, Massachusetts and 1 other locations) |
| Trial ID | NCT00471978 on ClinicalTrials.gov |
What this trial studies
This study analyzes DNA from blood and tissue samples of patients diagnosed with lung cancer to understand genetic factors associated with the disease. It aims to assess the impact of genetic polymorphisms on lung cancer risk, including the influence of diet and demographic factors. The research involves collecting blood samples and tissue from patients undergoing surgery, as well as questionnaires about their medical and environmental history. The goal is to identify biomarkers that could improve understanding and treatment of lung cancer.
Who should consider this trial
Good fit: Ideal candidates are newly diagnosed patients with primary lung cancer at Massachusetts General Hospital or Boston Medical Center Cancer Center.
Not a fit: Patients with metastasis from another site to the lung or those with mesothelioma will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better understanding of lung cancer genetics and improved strategies for prevention and treatment.
How similar studies have performed: Other studies have shown success in identifying genetic factors related to cancer, making this approach promising but not entirely novel.
Eligibility criteria
Show full inclusion / exclusion criteria
DISEASE CHARACTERISTICS:
* Patient:
* Newly diagnosed primary lung cancer
* Patient at Massachusetts General Hospital (MGH) or Boston Medical Center Cancer Center
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified
EXCLUSIONS:
Vulnerable populations are excluded. Patients with metastasis from another site to lung or mesothelioma are excluded.
Where this trial is running
Boston, Massachusetts and 1 other locations
- Massachusetts General Hospital — Boston, Massachusetts, United States (Recruiting)
- Harvard School of Public Health — Boston, Massachusetts, United States (Recruiting)
Study contacts
- Principal investigator: David C. Christiani, MD — Massachusetts General Hospital
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.